RetiSpec is a neurotechnology company developing non-invasive retinal imaging technology to identify biomarkers associated with neurodegenerative disease. The company leverages the biological connection between the retina and the brain to enable earlier and more accessible detection of neurological pathology.

Its platform combines retinal imaging with machine learning algorithms to analyze subtle molecular and structural signatures in the eye. These retinal biomarkers are used to infer brain-related disease processes, particularly those linked to Alzheimer’s disease and related neurodegenerative conditions.

RetiSpec’s technology is positioned for use in clinical and research settings as a screening and diagnostic support tool. The company frames its platform as a neuroimaging and biomarker discovery solution that expands neurological assessment beyond traditional brain imaging modalities.